Vaccines against cancer and heart disease could be ready by the end of the decade, according to Moderna’s chief executive.
Dr Paul Burton, said the advancements made in the field of mRNA — the technology used to make his company’s flagship Covid shot — have ushered in a golden era of vaccines.
He predicts that by 2030 there will be vaccines for ‘all sorts’ of incurable conditions, saving ‘hundreds of thousands, if not millions, of lives.’
Early studies have already shown ‘tremendous promise’, he added. But they are not likely to be your typical vaccine — they will need to be highly personalized and expensive.
Heart disease and cancer are the biggest killers in the US, behind 1.3million fatalities annually — or more than one in three of all deaths recorded.
Dr Paul Burton, the chief executive of the vaccine maker, told The Guardian: ‘We will have that vaccine and it will be highly effective, and it will save hundreds of thousands, if not millions, of lives.
‘I think we will be able to offer personalized cancer vaccines against multiple different tumor types to people around the world.’
He added: ‘I think what we have learned in recent months is that if you ever thought that mRNA was just for infectious diseases, or just for Covid, the evidence now is that that’s absolutely not the case.
‘It can be applied to all sorts of disease areas; We are in cancer, infectious diseases, cardiovascular disease, autoimmune diseases, rare diseases.
‘We have studied in all of those areas and they have all shown tremendous promise.’
Dr Burton did not say how the vaccines would work, but previous studies have shown how mRNA could be used to fight cancer.
MRNA vaccines work by instructing cells to produce a protein that triggers an immune response against a specific pathogen, like Covid.
Source: dailymail
Disclaimer: Opinions expressed here are those of the writers and do not reflect those of Peacefmonline.com. Peacefmonline.com accepts no responsibility legal or otherwise for their accuracy of content. Please report any inappropriate content to us, and we will evaluate it as a matter of priority. |
Featured Video